References:
1. The Management of Nausea and Vomiting of Pregnancy and Hyperemesis Gravidarum (Green-top Guideline No. 69) [Internet]. Royal College of Obstetricians & Gynaecologists. [cited 2020 Feb 25]. Available from: https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg69/
2. Fiaschi L, Nelson-Piercy C, Deb S, King R, Tata LJ. Clinical management of nausea and vomiting in pregnancy and hyperemesis gravidarum across primary and secondary care: a population-based study. BJOG Int J Obstet Gynaecol. 2019 Sep;126(10):1201–11.
3. Taylor LG, Bird ST, Sahin L, Tassinari MS, Greene P, Reichman ME, et al. Antiemetic use among pregnant women in the United States: the escalating use of ondansetron. Pharmacoepidemiol Drug Saf. 2017 May;26(5):592–6.
4. Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 189: Nausea And Vomiting Of Pregnancy. Obstet Gynecol. 2018;131(1):e15–30.
5. Updated Signal assessment report on birth defects following in-utero exposure during the first trimester of pregnancy arising from recent publications with ondansetron [Internet]. 2019 [cited 2020 Feb 25]. Available from: https://www.ema.europa.eu/en/documents/prac-recommendation/updated-signal-assessment-report-birth-defects-following-utero-exposure-during-first-trimester_en.pdf
6. Ondansetron 4 mg film-coated tablets - Summary of Product Characteristics (SmPC) - (emc) [Internet]. [cited 2020 Feb 25]. Available from: https://www.medicines.org.uk/emc/product/5222/smpc#PREGNANCY
7. Kaplan YC, Richardson JL, Keskin-Arslan E, Erol-Coskun H, Kennedy D. Use of ondansetron during pregnancy and the risk of major congenital malformations: A systematic review and meta-analysis. Reprod Toxicol Elmsford N. 2019;86:1–13.
8. Huybrechts KF, Hernández-Díaz S, Straub L, Gray KJ, Zhu Y, Patorno E, et al. Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring. JAMA. 2018 18;320(23):2429–37.
9. Zambelli-Weiner A, Via C, Yuen M, Weiner DJ, Kirby RS. First trimester ondansetron exposure and risk of structural birth defects. Reprod Toxicol Elmsford N. 2019;83:14–20.
10. Schachtman Law » Litigation Science – In re Zambelli-Weiner [Internet]. [cited 2020 Feb 27]. Available from: http://schachtmanlaw.com/litigation-science-in-re-zambelli-weiner/
11. Huybrechts KF, Hernandez-Diaz S, Straub L, Gray KJ, Zhu Y, Mogun H, et al. Intravenous Ondansetron in Pregnancy and Risk of Congenital Malformations. JAMA. 2019 Nov 15;
12. Lemon LS, Bodnar LM, Garrard W, Venkataramanan R, Platt RW, Marroquin OC, et al. Ondansetron use in the first trimester of pregnancy and the risk of neonatal ventricular septal defect. Int J Epidemiol. 2019 Dec 20;
13. Källén B. Lumping or Splitting? In: Drugs During Pregnancy: Methodological Aspects. Springer 2016. pp89-91.
14. Scholz T, Reinking B. Congenital Heart Disease. In: Gleason A, Juul SE (eds). Avery’s Diseases of the Newborn. 10th edn. Philadelphia, PA: Elsevier, 2018.